Entering text into the input field will update the search result below

Compugen nabs new U.S. patent for COM902

  • The USPTO has granted Compugen (NASDAQ:CGEN) a new patent for COM902, its immuno-oncology therapeutic antibody targeting TIGIT.
  • U.S. Patent No. 10,751,415, titled "Anti-TIGIT Antibodies, Anti-PVRIG Antibodies and Combinations Thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). This patent is expected to expire in August 2037.
  • The Company has initiated Phase 1/2 escalation trial of COM902. Patient enrollment is on track with initial data anticipated in 2021, stated CEO Anat Dayag in Q2 Earnings Call Transcript.
  • CGEN rallied around 300% over the past year, with both Quant and Wall Street Rating of Very Bullish. The price target is $19.75.
  • Shares are up 3% premarket.

Recommended For You

About CGEN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CGEN--
Compugen Ltd.